Matching articles for "Evzio"
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • June 5, 2017; (Issue 1522)
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is
associated with economic hardship, social isolation,
incarceration, increased rates of...
Opioid use disorder is a chronic, relapsing disease with both physical and psychiatric components. It is
associated with economic hardship, social isolation,
incarceration, increased rates of blood-borne
infections such as HIV and viral hepatitis, adverse
pregnancy outcomes, and increased mortality.
According to the CDC, there were 33,091 deaths
related to opioid overdose in the US in 2015, more
than in any previous year. Several guidelines on the
management of opioid use disorder have recently
been published.
Naloxone (Narcan) Nasal Spray for Opioid Overdose
The Medical Letter on Drugs and Therapeutics • January 4, 2016; (Issue 1485)
The recent increase in deaths due to overdose of
heroin and prescription opioids in the US has renewed
interest in the opioid antagonist naloxone, particularly
in making it available to first responders and...
The recent increase in deaths due to overdose of
heroin and prescription opioids in the US has renewed
interest in the opioid antagonist naloxone, particularly
in making it available to first responders and to
relatives and close friends of persons using heroin or
taking prescription opioids. IV or IM administration
by healthcare professionals is preferred, but
peripheral venous access may be difficult to obtain
in IV drug abusers, and exposure to their blood may
be hazardous.
In Brief: A Naloxone Auto-Injector (Evzio)
The Medical Letter on Drugs and Therapeutics • June 9, 2014; (Issue 1444)
A recent Medical Letter article reported renewed interest in the intranasal administration (off-label) of the opioid antagonist naloxone because of an increase in deaths from opioid overdose in the US.1 Now the...
A recent Medical Letter article reported renewed interest in the intranasal administration (off-label) of the opioid antagonist naloxone because of an increase in deaths from opioid overdose in the US.1 Now the FDA has approved a more practical alternative for emergency treatment of life-threatening opioid overdose in adults and children: a single-dose naloxone auto-injector (Evzio – Kaleo) for intramuscular or subcutaneous use.
Evzio will be available in kits containing two prefilled 0.4-mg auto-injectors with voice guidance and a "trainer" device that also has voice guidance, but does not contain medication or a needle. The manufacturer has not published a price for Evzio to date, but news reports indicate that each kit could cost hundreds of dollars, compared to about $20 for a standard 0.4-mg injectable dose of naloxone, which can be given intranasally.
1. Intranasal naloxone for treatment of opioid overdose. Med Lett Drugs Ther 2014; 56:21.
Download complete U.S. English article
Evzio will be available in kits containing two prefilled 0.4-mg auto-injectors with voice guidance and a "trainer" device that also has voice guidance, but does not contain medication or a needle. The manufacturer has not published a price for Evzio to date, but news reports indicate that each kit could cost hundreds of dollars, compared to about $20 for a standard 0.4-mg injectable dose of naloxone, which can be given intranasally.
1. Intranasal naloxone for treatment of opioid overdose. Med Lett Drugs Ther 2014; 56:21.
Download complete U.S. English article